Company intelligence / Profile preview
Vaxxinity
United Statesvaxxinity.com ↗
- Ownership
- Public · VAXX
- Development stage
- Other
01
Overview
Vaxxinity has multiple programs in development. UB-311 is in Phase 2 for Alzheimer's disease, UB-312 is in Phase 1 for Parkinson's disease, and VXX-301 is in preclinical stage for Alzheimer's. Their COVID-19 vaccine UB-612 completed Phase 3 with positive topline data reported in December 2022.
- Therapeutic areas
- CardiovascularNeurologyInfectious Diseases
- Modalities
- Synthetic peptide immunotherapyActive Immunotherapy Medicines (AIMs)Vaccines
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Financials
- Market cap
- $1.6M
- Total revenue
- $0
- Enterprise value
- $-13.6M
Beyond the preview
Go deeper on Vaxxinity.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vaxxinity.